Moderna: Study shows vaccine candidate indicates durable immunity

 

• Moderna (NASDAQ:MRNA) says participants in the Phase 1 study led by the National Institute of Allergy and Infectious Diseases of mRNA-1273, its COVID-19 vaccine candidate, retained high levels of neutralizing antibodies through 119 days following the first vaccination and 90 days following the second vaccination.
• The interim Phase 1 data suggests that mRNA-1273 "can generate durable neutralizing antibodies across all age groups including in older and elderly adults," Moderna Chief Medical Officer Tal Zaks says. "These data give us further optimism to expect that the high level of efficacy recently demonstrated by mRNA-1273 to prevent COVID-19 disease will be durable."
• The company reaffirms it expects to have 100M-125M doses available globally in Q1 2021, including 85M-100M in the U.S. and 15M-25M available outside the U.S.
• The update follows Moderna's Nov. 30 announcement that the mRNA-1273's primary efficacy analysis of the Phase 3 study conducted on 196 cases confirmed the high efficacy observed at the first interim analysis, with the data analysis indicating a vaccine efficacy of 94.1%.
• https://seekingalpha.com/news/3641591-moderna-says-study-shows-vaccine-candidate-indicates-durable-immunity